Waters Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Udit Batra
- Full Time Employees
- 7,900
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 34 Maple Street Milford MA United States of America 01757
- IPO Date
- Nov 17, 1995
- CIK
- 0001000697
- Website
- waters.com
- Similar Companies
- Business
- Waters Corporation (NYSE: WAT), founded in 1958 and headquartered in Milford, Massachusetts, develops, manufactures, and markets analytical instruments, chromatography columns, and other consumables for the life sciences, pharmaceutical, biopharmaceutical, chemical, food, environmental, and clinical diagnostics industries worldwide. The company offers high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) systems such as the ACQUITY Premier and Alliance iS series; mass spectrometry instruments including the Xevo G3 QTof, Xevo TQ Absolute, SELECT SERIES MRT, and BioAccord LC-MS; gel permeation and size exclusion chromatography solutions; thermal analysis and rheology products through its TA Instruments division; light-scattering devices from Wyatt Technology; software platforms like Empower and waters_connect for data management and compliance; and related consumables, columns, detectors, and accessories used in drug discovery, development, manufacturing, food safety testing, environmental monitoring, and materials science applications across more than 100 countries with 12 manufacturing facilities and operations in 35 countries. Recent developments include the 2025 acquisition of Halo Labs to expand its biological analysis portfolio for advanced characterization in drug development; the July 2025 agreement to combine with BD's Biosciences and Diagnostic Solutions business in a $17.5 billion all-stock merger creating a leader in regulated life science and high-volume diagnostics testing; and the 2023 acquisition of Wyatt Technology enhancing its capabilities in macromolecular characterization and complex mixture analysis.
Waters (WAT) Earnings Expected to Grow: Should You Buy?
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
Assetmark Inc. Grows Stock Holdings in Waters Corporation $WAT
Nestle to Offload Half of Waters Business in Joint Venture With Platinum Equity
PitchBook Named Best Alternative Data Provider in Waters Technology Rankings 2026
Waters Corporation Is Getting Awfully Pricey
Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis
Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
Why Is Waters (WAT) Up 8.7% Since Last Earnings Report?
Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
Carnival: Calm Waters Despite Fuel Price Headwinds
Waters Corporation to Present at the Jefferies Global Healthcare Conference
Understanding Waters (WAT) Reliance on International Revenue
WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues